25322 Federal Register / Vol. 72, No. 86 / Friday, May 4, 2007 / Notices 

Peptide Inhibitors of Fibronectin and 

Related Collagen-Binding Proteins 

Description of Technology: 

Fibronectin has been implicated in a 

variety of cell contact processes, 

including cell attachment and 

migration. Fibronectin interacts with 

collagen through its gelatin-binding 

domain and this interaction is 

fundamental to the organization of 

extracellular matrices and the behavior 

of these cells on substrates. Fibronectin 

is essential for the attachment and 

migration of many cells, including 

various tumor and cancer cells. 

The issued patents disclose peptide 

compositions having binding affinity for 

fibronectin, as well as methods for 

binding fibronectin with a fibronectinbinding peptide and methods for 

inhibiting fibronectin-mediated cell 

adhesion. The peptides disclosed are 

derived from the extracellular matrix 

protein thrombospondin, which is a 

modular adhesive glycoprotein that 

binds to the gelatin binding domain of 

fibronectin. These peptides are strong 

inhibitors of fibronectin-mediated cell 

adhesion. As such, they may be 

applicable to a variety of indications 

including cancer, wound healing, and 

connective tissue diseases. 

Applications: 

1. Potential therapeutic use for 

applications such as cancer, wound 

healing, and connective tissue disease. 

2. Research tools for study of cell 

adhesion and migration processes. 

Inventors: David D. Roberts et al. 

(NCI) 

Related Publications: 

1. JM Sipes, N Guo, E Ne`gre, T Vogel, 

HC Krutzsch, DD Roberts. Inhibition of 

fibronectin binding and fibronectinmediated cell adhesion to collagen by a 

peptide from the second type I repeat of 

thrombospondin. J Cell Biol. 1993 

Apr;121(2):469–477. 

2. S Schultz-Cherry, H Chen, DF 

Mosher, TM Misenheimer, HC Krutzsch, 

DD Roberts, JE Murphy-Ullrich. 

Regulation of TGFbeta activity by 

peptides from the type I repeats of 

thrombospondin-1. J Biol Chem. 1995 

Mar 31;270(13):7304–7310. 

3. C Daniel, J Wiede, Y Takabatake, M 

Mizui, Y Isaka, E Imai, H Rupprecht, E 

Schulze-Lohoff, HC Krutzsch, SMF 

Ribeiro, DD Roberts, JE Murphy-Ullrich, 

C Hugo. Thrombospondin-1 is a major 

activator of TGFbeta in fibrotic renal 

disease in the rat in vivo. Kidney Int. 

2004 Feb;65(2):459–468. 

Patent Status: 

1. U.S. Patent No. 5,491,130 issued 13 

Feb 1996 (HHS Reference No. E–219– 

1992/0–US–01). 

2. U.S. Patent No. 5,849,701 issued 15 

Dec 1998 (HHS Reference No. E–219– 

1992/0–US–10). 

3. Foreign counterparts issued in 

Australia, Great Britain, France, 

Germany, and Japan. 

Related Technologies: 

1. Heparin- and Sulfatide-Binding 

Peptides From the Type I Repeats of 

Human Thrombospondin. 

a. U.S. Patent No. 5,357,041 issued 18 

Oct 1994 (HHS Reference No. E–198– 

1991/0–US–01); 

b. U.S. Patent No. 5,770,563 issued 23 

Jun 1998 (HHS Reference No. E–198– 

1991/2–US–01); 

c. U.S. Patent No. 6,051,549 issued 18 

Apr 2000 (HHS Reference No. E–198– 

1991/2–US–03); and 

d. foreign counterparts. 

2. Compositions for Stimulating TGF 

Activity. 

a. U.S. Patent No. 6,384,189 issued 07 

May 2003 (HHS Reference No. E–019– 

1994/1–US–02) 

Licensing Availability: Available for 

exclusive or non-exclusive licensing. 

Licensing Contact: Tara Kirby, PhD; 

301/435–4426; tarak@mail.nih.gov. 

Collaborative Research Opportunity: 

The National Cancer Institute, 

Laboratory of Pathology, is seeking 

statements of capability or interest from 

parties interested in collaborative 

research to further develop, evaluate, or 

commercialize these peptides. Please 

contact John D. Hewes, Ph.D. at (301) 

435–3121 or hewesj@mail.nih.gov for 

more information. 

Dated: April 27, 2007. 

Steven M. Ferguson, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. E7–8500 Filed 5–3–07; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the meeting of the 

President’s Cancer Panel. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(9)(b), Title 5 U.S.C., as 

amended, because the premature 

disclosure of information and the 

discussions would likely to significantly 

frustrate implementation of 

recommendations. 

Name of Committee: President’s Cancer 

Panel. 

Date: May 24, 2007. 

Time: 12:30 p.m. to 2:30 p.m. 

Agenda: The Panel will review the final 

draft of 2006/2007 Annual Report to the 

President. 

Place: National Cancer Institute, National 

Institutes of Health, Building 6116, Room 

212, 6116 Executive Boulevard, Bethesda, 

MD 20892, (Telephone Conference Call). 

Contact Person: Abby Sandler, PhD, 

Executive Secretary, Chief, Institute Review 

Office, Office of the Director, National Cancer 

Institute, National Institutes of Health, 

Building 6116, Room 212, MSC 8349, 6116 

Executive Boulevard, Bethesda, MD 20892– 

8349, 301/451–9399, sandlera@mail.nih.gov. 

Information is also available on the 

Institute’s/Center’s home page: 

deainfo.nci.nih.gov/advisory/pcp/pcp.htm, 

where an agenda and any additional 

information for the meeting will be posted 

when available. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS) 

Dated: April 26, 2007. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–2190 Filed 5–3–07; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Diabetes and 

Digestive and Kidney Diseases; Notice 

of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 

Special Emphasis Panel, NIDDK Diabetes 

Centers Applications. 


cprice-sewell on DSK89S0YB1PROD with NOTICES
Federal Register / Vol. 72, No. 86 / Friday, May 4, 2007 / Notices 25323 

Date: July 22–24, 2007. 

Time: 3 p.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Gaithersburg Marriott Washington 

Center, 9751 Washingtonian Boulevard, 

Gaithersburg, MD 20878. 

Contact Person: Atul Sahai, PhD, Scientific 

Review Administrator, Review Branch, DEA, 

NIDDK, National Institutes of Health, Room 

908, 6707 Democracy Boulevard, Bethesda, 

MD 20892, (301) 594–2242, 

sahaia@niddk.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.847, Diabetes, 

Endocrinology and Metabolic Research; 

93.848, Digestive Diseases and Nutrition 

Research; 93.849, Kidney Diseases, Urology 

and Hematology Research, National Institutes 

of Health, HHS). 

Dated: April 27, 2007. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–2184 Filed 5–3–07; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Diabetes and 

Digestive and Kidney Diseases; Notice 

of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 

Special Emphasis Panel, R–13 Conference 

Applications. 

Date: May 14, 2007. 

Time: 2 p.m. to 4 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, Two 

Democracy Plaza, 6707 Democracy 

Boulevard, Bethesda, MD 20892, (Telephone 

Conference Call). 

Contact Person: D.G. Patel, PhD, Scientific 

Review Administrator, Review Branch, DEA, 

NIDDK, National Institutes of Health, Room 

914, 6707 Democracy Boulevard, Bethesda, 

MD 20892–5452, (301) 594–7682, 

pateldg@niddk.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.847, Diabetes, 

Endocrinology and Metabolic Research; 

93.848, Digestive Diseases and Nutrition 

Research; 93.849, Kidney Diseases, Urology 

and Hematology Research, National Institutes 

of Health, HHS) 

Dated: April 27, 2007. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–2185 Filed 5–3–07; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Deafness and 

Other Communication Disorders; 

Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Communication 

Disorders Review Committee, CDRC. 

Date: June 21–22, 2007. 

Time: June 21, 2007, 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Wyndham Hotel, 101 W. Fayette 

Street, Baltimore, MD 21201. 

Time: June 22, 2007, 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Wyndham Hotel, 101 W. Fayette 

Street, Baltimore, MD 21201. 

Contact Person: Sheo Singh, PhD, 

Scientific Review Administrator, Scientific 

Review Branch, Division of Extramural 

Activities, Executive Plaza South, Room 

400C, 6120 Executive Blvd., Bethesda, MD 

20892, 301–496–8683. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.173, Biological Research 

Related to Deafness and Communicative 

Disorders, National Institutes of Health, 

HHS). 

Dated: April 26, 2007. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–2187 Filed 5–3–07; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Alcohol Abuse 

and Alcoholism; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Alcohol Abuse and Alcoholism Initial 

Review Group, Clinical and Treatment 

Subcommittee. 

Date: June 5–6, 2007. 

Time: 8:30 a.m. and 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Crown Plaza—Silver Spring, 8777 

Georgia Avenue, Silver Spring, MD 20910. 

Contact Person: Katrina L Foster, PhD, 

Scientific Review Administrator, National 

Inst on Alcohol Abuse & Alcoholism, 

National Institutes of Health, 5635 Fishers 

Lane, Rm. 3042, Rockville, MD 20852, 301– 

443–4032, katrina@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.271, Alcohol Research 

Career Development Awards for Scientists 

and Clinicians; 93.272, Alcohol National 

Research Service Awards for Research 

Training; 93.273, Alcohol Research Programs; 

93.891, Alcohol Research Center Grants, 

National Institutes of Health, HHS) 

Dated: April 26, 2007. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–2191 Filed 5–3–07; 8:45 am] 

BILLING CODE 4140–01–M 


cprice-sewell on DSK89S0YB1PROD with NOTICES